Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Lupin has informed that it has enclosed a Press Release on 19th February 2021 as regards receipt of USFDA approval for the Company's Droxidopa Capsules, 100 mg, 200 mg and 300 mg, to market a generic equivalent of Northera Capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA.
The above information is a part of company’s filings submitted to BSE.